Estrogen Patch
Phase 3
Estrogen Patch is one of 14 therapeutic programs targeting Premature ovarian insufficiency. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
23 competitors in Premature Ovarian Insufficiency
#DrugCompanyPhaseTrials
1Estrace
Novo NordiskApproved
Zoladex
TTerSera Therapeutics LLC
Approved
Activella
Eli LillyPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Prometrium
FerringPhase 3
Rituxan
RochePhase 2
Depo-Provera
Eli LillyPhase 2
NEUPOGEN
AmgenPhase 2
Combined Oral Contraceptives
VViatris Innovation GmbH
Phase 3
Platelet Rich Plasma
ZZagazig University
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Premature ovarian insufficiency1 trial
Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency
Recruiting·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 3·NCT06851754·185 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Estrogen Patch. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]